Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

dna-163466

China conducts first gene-editing human trial

November 21, 2016 Research and Development, Sales and Marketing China, DNA, cas9, crispr

China has used Crispr/Cas9 gene-editing technology to edit the DNA of a human subject, suffering from metastatic lung cancer. This …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
News
clinical_trial

GSK/J&J release how their drug measures up against Humira

November 18, 2016 Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …
News
flag_of_japan_

Japan to slash Opdivo costs by 50%

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo

Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …
News
amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
News
nice_reception

NICE rules Shire’s Onivyde not cost effective

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
News
images

NICE approves Roche’s Perjeta for breast cancer

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
News

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
News
placebo

Surprising number of parents agree to use of placebos in children

November 16, 2016 Medical Communications, Research and Development Placebo, children

A study by Boston Children’s Hospital found that parents recognised that placebos are a vital part of research and that …
News
shutterstock_292920209

Real world evidence: a reality check for pharma?

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence

Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …
Feature
msd

Powerful new data for MSD’s bladder cancer drug stops trial early

November 16, 2016 Research and Development MSD, pembrolizumab

MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …
News

Abbott-St. Jude $25 billion deal close to clearance

November 16, 2016 Research and Development, Sales and Marketing Abbott, St. Jude, acquisition

EU antitrust regulators are due to reach a decision on the deal on 23 November that would see Abbott Laboratories …
News
janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016 Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …
News
celgene_1_02

NICE rejects Celegene’s Revlimid as second-line treatment

November 16, 2016 Research and Development, Sales and Marketing Celegene, Revlimid

NICE has decided Celegene’s multiple myeloma growth engine Revlimid (lenalidomide) will not be offered to patients as a second line …
News
nordic-nanovector-big

New CMO and Executive Management Team member for Nordic Nanovector

November 15, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Nordic Nanovector has recruited a new chief medical officer (CMO) and Executive Management Team member with the appointment of Dr …
Appointment
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026